Skip to main content

Heather Elizabeth Whitson

Duke School of Medicine Distinguished Professor in Neuroscience
Medicine, Geriatrics and Palliative Care
Duke Box 3003, Durham, NC 27710
Dept of Medicine, Durham, NC 27710

Overview


Dr. Whitson is a geriatrician, memory care specialist, and clinical researcher.  Her career is focused on improving care options and resilience for people with multiple chronic conditions.  In particular, she has interest and expertise related to how aging biology and comorbidities impact brain health and risk for Alzheimer's disease. She is co-director of the Duke/UNC Alzheimer's Disease Research Center (Duke/UNC ADRC), which aims to transform dementia care and research in Eastern North Carolina while developing novel preventions and treatment strategies for Alzheimer's disease by identifying aging-related factors across the lifespan that drive risk, progression, or experience of dementia. The Duke/UNC ADRC conducts the Memory and Aging Study, which is tracking brain and cognitive changes in over 400 individuals at risk for dementia in later life.  Dr. Whitson also co-Chairs the Alzheimer's Association's Clinical Practice Guideline panel for the use of blood-based biomarkers in the diagnosis of Alzheimer's disease. As a thought leader in a national collaborative focused on the biomedical aspects of resilience, Dr. Whitson seeks to better understand biological, psychological, and contextual factors that determine how well we "bounce back" after acute health stressors and why our resilience capacity changes with age. Dr. Whitson has contributed to work examining resilience to many types of health stressors, including surgery, dialysis, infection, vascular events, and vision loss - often focused on how these stressors affect the brain.  She has led multiple studies to examine how the aging brain responds to the late-life stressor of vision loss, and she has developed a rehabilitation model to improve independence in older adults living with comorbid impairments in vision and cognition. 

Current Duke Appointments & Affiliations


Duke School of Medicine Distinguished Professor in Neuroscience · 2024 - Present Medicine, Geriatrics and Palliative Care, Medicine
Professor of Medicine · 2020 - Present Medicine, Geriatrics and Palliative Care, Medicine
Professor in Ophthalmology · 2020 - Present Ophthalmology, Vitreoretinal Diseases & Surgery, Ophthalmology
Professor in Head & Neck Surgery and Communication Sciences · 2021 - Present Head and Neck Surgery & Communication Sciences, Clinical Science Departments
Professor in Neurology · 2022 - Present Neurology, Clinical Science Departments
Director of the Duke Center for the Study of Aging and Human Development · 2008 - Present Center for the Study of Aging and Human Development, Institutes and Centers

Recent News Items


Published October 5, 2026
How to Work Together
Published September 2, 2026
The Fleeting Moments of Clarity in Dementia Patients
Published July 31, 2026
MADE FOR THIS Campaign Hits the Road

View All News Items

Recent Scholarly Works


An Exploratory Stability Selection (ESS) framework for robust predictor discovery: An application to physical resilience in aging populations.

Journal article Exp Gerontol · October 15, 2026 Identifying biological and clinical signals that consistently predict physical resilience, defined as one's ability to maintain or regain function following a health stressor, is essential for advancing precision approaches to aging and recovery. High-dime ... Full text Link to item Cite

Differential Associations of Postoperative Plasma and Cerebrospinal Fluid Albumin Changes with Delirium Following Non-Cardiac Surgery.

Journal article medRxiv · September 21, 2026 BACKGROUND: Postoperative increases in cerebrospinal fluid (CSF) to plasma albumin ratio (CPAR), a blood-brain barrier dysfunction marker, have been associated with postoperative delirium (POD) and prolonged hospital stay. However, the contributions of pla ... Full text Link to item Cite

Clinical Practice Outcomes With Lecanemab for Alzheimer Disease.

Journal article Neurol Open Access · September 2026 BACKGROUND AND OBJECTIVES: Lecanemab, an antiamyloid monoclonal antibody, received US Food and Drug Administration approval in July 2023 to treat amyloid-positive early stages of Alzheimer disease (AD) and has since been adopted in many countries. The prim ... Full text Link to item Cite
View All Scholarly Works

Recent Grants


Duke/UNC Alzheimer's Disease Research Center

ResearchPrincipal Investigator · Awarded by National Institute on Aging · 2021 - 2031

Integrated Training in Anesthesiology Research

Inst. Training Prgm or CMEMentor · Awarded by National Institute of General Medical Sciences · 1996 - 2031

Characterization and Diagnosis of Alzheimer's Disease Using mRNA Biomarkers

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2026 - 2031

View All Grants

Education


Duke University · 2009 M.H.S.
Cornell University · 2000 M.D.